Discover a groundbreaking webinar delving into the future of dry eye clinical trial design and execution for emerging treatments. A highly prevalent multi-factorial disease affecting millions of patients, dry eye disease can still today be a challenging condition to treat. While recent advancements offer additional tools and novel mechanisms of action for clinicians, there are still significant treatment gaps requiring innovation.
The challenge, however, is that these new treatments under development today often require a different approach to clinical trials compared to predecessors. From the need to prove the impact on both clinical signs and patient symptoms to reducing the impact of influential environmental or lifestyle facets, how researchers approach clinical trial design can make or break program success.
In this webinar, featured speakers George Ousler, Ora Senior Vice President of Anterior Segment, and Dr. Ethan Bensinger, Visual Psychophysics Specialist and Ora Director of R&D New Technology, will discuss ways to optimize dry eye clinical trial designs and execution. During this talk, attendees will hear about techniques and protocol approaches to improve endpoint sensitivity, reduce screen failure rates and increase harmonization across sites. The discussion will also include insights on trial designs, endpoint selection, recruitment, and methods to reduce data variability
Ora, Inc. is the only ophthalmic clinical trials company with a research and development (R&D) department focused on the evolution of clinical trials. Join this webinar for an engaging discussion on how important lessons learned from Ora’s over 30 years of experience are being leveraged to design and conduct the dry eye clinical studies of the future.
George W. Ousler III, Senior Vice President, Anterior Segment, Ora
As Senior Vice President of the Anterior Segment at Ora, George Ousler oversees all dry eye clinical programs, lending his therapeutic knowledge and expertise to see each project through to completion. He establishes clinical models and regulatory pathways for the evaluation of dry eye therapies and has studied many of the agents under investigation. The Anterior Segment Department includes over 150 team members who work with global clients in the US, Europe and Asia.
George has over 20 years of pioneering pharmaceutical development experience in the area of dry eye. He is frequently called on to consult on worldwide drug development and registration. He has authored over 250 publications on the topic and has been invited to present his research at numerous national and international symposia. He also holds several patents on techniques, formulations and methods in dry eye and related conditions.
Dr. Ethan Bensinger, PhD, Visual Psychophysics Specialist, Ora Director of R&D New Technology
As a Clinical Scientist for Ora Research and Development, Dr. Ethan Bensinger helps create and improve upon clinically meaningful diagnostic tests and develops novel technologies used to make ophthalmic clinical research more efficient, accurate and patient-centric. He also constructs systems used to evaluate the suitability and effectiveness of currently accepted endpoints or to investigate new ones.
Dr. Bensinger conducts research on a variety of ophthalmic conditions, authoring or co-authoring multiple research publications printed in academic journals and presenting posters or papers at industry research conferences. With more than half a decade of formal ophthalmic research experience, Dr. Bensinger specializes in retinal imaging and optics, with a focus on structure and function relationships.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Clinical trial sponsors
- Investigators and medical professionals executing clinical trials in their practice
- Leaders of clinical development start-ups
- Ophthalmic medical professionals interested in clinical research
What You Will Learn
In this webinar, attendees will learn:
- Ways to optimize dry eye disease clinical trial designs and execution for future treatments currently in the pipeline
- Dry eye disease trial composition, endpoint selection and methods and models that together reduce data variability and increase the likelihood of program success
- Techniques and protocol approach to improve endpoint sensitivity, reduce screen failure rates and increase harmonization across sites
Ora is the world’s leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 80 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, and follow us on LinkedIn.
Ora® and Ora Logo are registered trademarks of Ora, Inc.